SCHEMBL19398197

SCHEMBL19398197

O=C(N/C=C/c1ccccc1)Nc1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.79
▸ NPC1 O15118 5/20 0.79
▸ RAB9A P51151 4/20 0.79
▸ SMN1; SMN2 Q16637 4/20 0.79
▸ MAPT P10636 3/20 0.79
▸ LMNA P02545 3/20 0.79
▸ MEN1 O00255 2/20 0.79
▸ KMT2A Q03164 2/20 0.79
▸ KDM4E B2RXH2 1/20 0.79
▸ MAOB P27338 4/20 0.58
▸ MAOA P21397 2/20 0.58
▸ MMP1 P03956 2/20 0.58
▸ MMP2 P08253 2/20 0.58
▸ MMP9 P14780 2/20 0.58
▸ EGFR P00533 1/20 0.58
▸ TP53 P04637 1/20 0.57
▸ EPHX1 P07099 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ EPHX2 P34913 1/20 0.57
▸ CDK9 P50750 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17664262 0.96 ALDH1A1 (0.84) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL27941307 0.89 RAB9A (0.73) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL19403902 0.82 HDAC1 (0.79) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL18229945 0.81 MAPT (0.68) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL11996396 0.81 SMN1; SMN2 (0.68) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL11996395 0.81 SMN1; SMN2 (0.68) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL4358906 0.80 MEN1 (0.65) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL4816796 0.80 MEN1 (0.65) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL22284093 0.79 ALDH1A1 (0.61) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL28774232 0.79 SMN1; SMN2 (0.59) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170273922-A1 UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2017-09-28 — — US disclosed
US-20170273922-A1 UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2017-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170273922-A1 UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS AR, UTS2R, SHBG ALDH1A1 1583/4885NPC1 2234/4885RAB9A 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback